Stay updated with breaking news from Biocon Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biotechnology major Biocon is recalling 3,665 bottles of antifungal medication in the US market for "failed degradation specifications", according to the US Food and Drug Administration (USFDA).
USFDA noted that the New Jersey-based Biocon Pharma Inc is recalling the affected lot due to ‘Failed Impurities/Degradation Specifications: High Out Of Specification degradation results’.
The biologics license application was filed for Bevacizumab by Biocon’s partner Viatris
India's healthcare firms spent $4.32 billion during January to June of 2022 on mergers and acquisitions, compared to $2.02 billion in the same period last year
Biocon Biologics Ltd., a subsidiary of Biocon Ltd, announced today that it has successfully completed its multi-billion-dollar acquisition of the global biosimilars business of its partner Viatris Inc.